Anebulo Pharmaceuticals (NASDAQ:ANEB) Announces Quarterly Earnings Results

Anebulo Pharmaceuticals (NASDAQ:ANEB) issued its earnings results on Friday. The company reported ($0.09) EPS for the quarter, Zacks reports.

Anebulo Pharmaceuticals Price Performance

Anebulo Pharmaceuticals stock opened at $1.33 on Friday. The business has a 50 day moving average of $1.51 and a 200-day moving average of $1.74. Anebulo Pharmaceuticals has a 1 year low of $0.80 and a 1 year high of $3.30.

Wall Street Analysts Forecast Growth

Separately, Benchmark reissued a “speculative buy” rating and set a $8.00 target price on shares of Anebulo Pharmaceuticals in a research note on Tuesday, November 19th.

Insider Activity at Anebulo Pharmaceuticals

In other Anebulo Pharmaceuticals news, Director Aron R. English purchased 10,101,010 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were purchased at an average cost of $0.99 per share, for a total transaction of $9,999,999.90. Following the acquisition, the director now owns 15,467,300 shares of the company’s stock, valued at approximately $15,312,627. This represents a 188.23 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 85.90% of the stock is currently owned by company insiders.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.